Literature DB >> 14555234

p73 and p63 protein stability: the way to regulate function?

Carine Maisse1, Piero Guerrieri, Gerry Melino.   

Abstract

While the p53 homologue p73 has been found to be involved in tumorigenesis, the molecular mechanisms involved in this function are still not fully evident. The presence of two distinct promoters allows the formation of two proteins with opposite effects: while TA-p73 shows pro-apoptotic effects, DeltaN-p73 has an evident anti-apoptotic function. The relative expression of the two proteins is in fact related to the prognosis of several cancers. Since both p73 and p63, the other member of the same family, share the ability to interact with each other, it is important to understand the mechanisms that control the degradation and stability of both proteins, and their relative isoforms. p73 and p63 stability is regulated not only by protein modifications (phosphorylation, acetylation) but also by its degradation in the proteasome. To this end, the interaction with Mdm2, p300/CBP, and SUMO-1 are discussed in details.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14555234     DOI: 10.1016/s0006-2952(03)00511-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  Expression of p63 and p16 in primary and recurrent pterygia.

Authors:  Fernando S Ramalho; Claudia Maestri; Leandra N Z Ramalho; Alfredo Ribeiro-Silva; Erasmo Romão
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-08       Impact factor: 3.117

2.  Overexpression and ratio disruption of ΔNp63 and TAp63 isoform equilibrium in endometrial adenocarcinoma: correlation with obesity, menopause, and grade I/II tumors.

Authors:  Eleni Vakonaki; Nikolaos Soulitzis; Stavros Sifakis; Danae Papadogianni; Dimitrios Koutroulakis; Demetrios A Spandidos
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-24       Impact factor: 4.553

3.  Combined p53-related genetic variants together with HPV infection increase oral cancer risk.

Authors:  Zhongqiu Wang; Erich M Sturgis; Yang Zhang; Zhigang Huang; Qi Zhou; Qingyi Wei; Guojun Li
Journal:  Int J Cancer       Date:  2011-12-02       Impact factor: 7.396

4.  DNA-binding and transactivation activities are essential for TAp63 protein degradation.

Authors:  Haoqiang Ying; Donny L F Chang; Hongwu Zheng; Frank McKeon; Zhi-Xiong Jim Xiao
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

Review 5.  The Tail That Wags the Dog: How the Disordered C-Terminal Domain Controls the Transcriptional Activities of the p53 Tumor-Suppressor Protein.

Authors:  Oleg Laptenko; David R Tong; James Manfredi; Carol Prives
Journal:  Trends Biochem Sci       Date:  2016-09-23       Impact factor: 13.807

Review 6.  p53 ancestry: gazing through an evolutionary lens.

Authors:  Wan-Jin Lu; James F Amatruda; John M Abrams
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

7.  SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53.

Authors:  Cian J Lynch; Zahid H Shah; Simon J Allison; Shafiq U Ahmed; Jack Ford; Lorna J Warnock; Han Li; Manuel Serrano; Jo Milner
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

8.  HDM2 regulation by AURKA promotes cell survival in gastric cancer.

Authors:  Vikas Sehdev; Ahmed Katsha; Janet Arras; Dunfa Peng; Mohammed Soutto; Jeffrey Ecsedy; Alexander Zaika; Abbes Belkhiri; Wael El-Rifai
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

9.  Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin.

Authors:  Poramaporn Klanrit; Marcella B Flinterman; Edward W Odell; Gerry Melino; Richard Killick; James S Norris; Mahvash Tavassoli
Journal:  Cell Cycle       Date:  2007-11-16       Impact factor: 4.534

10.  New p63 targets in keratinocytes identified by a genome-wide approach.

Authors:  M Alessandra Viganò; Jérôme Lamartine; Barbara Testoni; Daniele Merico; Daniela Alotto; Carlotta Castagnoli; Amèlie Robert; Eleonora Candi; Gerry Melino; Xavier Gidrol; Roberto Mantovani
Journal:  EMBO J       Date:  2006-10-12       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.